Edesa Biotech Inc. has released its financial results for the six months ended March 31, 2025. The company reported a net loss of $3.2 million, compared to a net loss of $3.5 million for the same period in 2024. Total operating expenses decreased by $0.6 million to $3.5 million from $4.1 million in the previous year. Other income also saw a decline, decreasing by $208,000 to $331,000, primarily due to a reduction in interest income and reimbursement funding from the Canadian government's Strategic Innovation Fund. For the quarter ended March 31, 2025, Edesa reported a net loss of $1.6 million, an improvement from the $1.9 million loss reported in the same quarter of 2024. Total operating expenses for the quarter decreased by $0.6 million to $1.6 million, while other income fell by $311,000 to $49,000. As of March 31, 2025, Edesa had cash and cash equivalents totaling $13.9 million and working capital of $13.5 million. Looking ahead, Edesa plans to submit drug manufacturing data to the U.S. Food and Drug Administration (FDA) for its investigational new drug application in the second half of 2025, with topline results anticipated within 12 to 18 months following regulatory clearance. The planned Phase 2 study has already been approved in Canada. Edesa Biotech also announced its participation in the upcoming BIO International Convention in Boston from June 16-19, 2025.